ArticleMolecular therapy. Advances2026
A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Development of Vaccine Platforms, With a Particular Focus on the COVID-19 Pandemic.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic was controlled by active vaccination, but emergence of viral mutations in the receptor-binding domain (RBD) of the spike (S) protein supported the need for vaccines targeting genetically stable viral domains. We developed a unique vaccine (OC-007) combining WH1-, Alpha-, and Beta-variant RBD loops; the membrane (M; WH1); and nucleoproteins (N; WH1). In a first-in-human, placebo-controlled, randomized, double-blind, dose-escalation phase 1 clinical trial, the OC-007 DNA vaccine was evaluated as one booster dose delivered intramuscularly by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.